Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme

HIV Medicine

Volumn 11, Issue 5, 2010, Pages 299-307

  Moore, D M ^a,b   Zhang, W ^a   Yip, B ^a   Genebat, M ^d   Lima, V D ^a   Montaner, J S G ^a,b   Hogg, R S ^a,c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Access to therapy; Adherence; Antiretroviral therapy; Treatment interruptions

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; TENOFOVIR; ANTIRETROVIRUS AGENT;

ADULT; AGE; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH CARE ACCESS; HEALTH INSURANCE; HEALTH PROGRAM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETREATMENT; SEX DIFFERENCE; TREATMENT OUTCOME; ADOLESCENT; COMPLICATION; HEALTH CARE DELIVERY; HIV INFECTIONS; IMMUNOLOGY; MEDICATION COMPLIANCE; PREGNANCY; PROPORTIONAL HAZARDS MODEL; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PREGNANCY; PROPORTIONAL HAZARDS MODELS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953172306     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00779.x     Document Type: Article

References (23)

1. Hogg RS, Heath KV, Yip B. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
2. Jahn A, Floyd S, Crampin AC. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008, 371:1603-1611.
3. Montaner JS, Hogg R, Wood E. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006, 368:531-536.
4. Fang CT, Hsu HM, Twu SJ. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004, 190:879-885.
5. Oyugi JH, Byakika-Tusiime J, Ragland K. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007, 21:965-971.
6. Pence BW, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:194-201.
7. Strathdee SA, Palepu A, Cornelisse PG. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
8. Joy R, Druyts EF, Brandson EK. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008, 47:500-505.
9. Mocroft A, Phillips AN, Soriano V. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005, 21:743-752.
10. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414.
11. Ahdieh-Grant L, Tarwater PM, Schneider MF. Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005, 38:500-503.
12. Kerr T, Marshall A, Walsh J. Determinants of HAART discontinuation among injection drug users. AIDS Care 2005, 17:539-549.
13. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006, 7:156-162.
14. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Phys AIDS Care (Chicago, IL) 2002, 1:95-103.
15. Hammer SM, Eron JJ, Reiss P. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555-570.
16. http://www.cfenet.ubc.ca/webuploads/files/06_2826_TherapeuticGuidelines_3.pdf, British Columbia Centre for Excellence in HIV/AIDS., Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Available at, (accessed 23 July 2008)
17. Wood E, Kerr T, Tyndall MW. Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users. Addiction 2007, 102:1503-1505.
18. Alfonso V, Bermbach N, Geller J, Montaner JS. Individual variability in barriers affecting people's decision to take HAART: a qualitative study identifying barriers to being on HAART. AIDS Patient Care STDS 2006, 20:848-857.
19. Pence BW, Miller WC, Gaynes BN, Eron JJ. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:159-166.
20. Shannon K, Bright V, Duddy J, Tyndall MW. Access and utilization of HIV treatment and services among women sex workers in Vancouver's downtown eastside. J Urban Health 2005, 82:488-497.
21. Lima VD, Kretz P, Palepu A. Aboriginal status is a prognostic factor for mortality among antiretroviral naive HIV-positive individuals first initiating HAART. AIDS Res Ther 2006, 3:14.
22. Weidle PJ, Wamai N, Solberg P. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587-1594.
23. El-Sadr WM, Lundgren JD, Neaton JD. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.